Ignacio Matos

4.9k total citations
57 papers, 818 citations indexed

About

Ignacio Matos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ignacio Matos has authored 57 papers receiving a total of 818 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Ignacio Matos's work include Cancer Immunotherapy and Biomarkers (17 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer Genomics and Diagnostics (8 papers). Ignacio Matos is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer Genomics and Diagnostics (8 papers). Ignacio Matos collaborates with scholars based in Spain, United States and United Kingdom. Ignacio Matos's co-authors include Elena Garralda, Josep Tabernero, Vivek Subbiah, Funda Meric‐Bernstam, Lipika Goyal, Dhakshina Moorthy Ganeshan, Hendrik‐Tobias Arkenau, Ishwaria M. Subbiah, Jacob J. Adashek and Arjun K. Menta and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Cancer Research.

In The Last Decade

Ignacio Matos

52 papers receiving 806 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ignacio Matos 521 206 195 145 137 57 818
Bin Meng 334 0.6× 186 0.9× 245 1.3× 136 0.9× 152 1.1× 62 814
Stefano Sioletic 241 0.5× 282 1.4× 214 1.1× 53 0.4× 99 0.7× 27 719
Alessandra Bisagni 285 0.5× 259 1.3× 172 0.9× 73 0.5× 106 0.8× 51 765
Heather M. Shaw 352 0.7× 132 0.6× 349 1.8× 93 0.6× 52 0.4× 34 725
Hidenori Mizugaki 400 0.8× 231 1.1× 207 1.1× 72 0.5× 45 0.3× 40 710
Shafei Wu 440 0.8× 338 1.6× 172 0.9× 52 0.4× 162 1.2× 59 720
Ashraf S. Mahmoud-Ahmed 242 0.5× 226 1.1× 135 0.7× 83 0.6× 158 1.2× 12 572
Alessia Caleo 310 0.6× 139 0.7× 271 1.4× 53 0.4× 227 1.7× 38 950
Pierre Bohanes 592 1.1× 266 1.3× 350 1.8× 110 0.8× 213 1.6× 52 1.0k
Zishuo I. Hu 748 1.4× 378 1.8× 217 1.1× 197 1.4× 225 1.6× 12 1.2k

Countries citing papers authored by Ignacio Matos

Since Specialization
Citations

This map shows the geographic impact of Ignacio Matos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Matos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Matos more than expected).

Fields of papers citing papers by Ignacio Matos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ignacio Matos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Matos. The network helps show where Ignacio Matos may publish in the future.

Co-authorship network of co-authors of Ignacio Matos

This figure shows the co-authorship network connecting the top 25 collaborators of Ignacio Matos. A scholar is included among the top collaborators of Ignacio Matos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ignacio Matos. Ignacio Matos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aliseda, Daniel, Jorge Arredondo, Javier Rodríguez, et al.. (2024). Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis. British journal of surgery. 111(2). 6 indexed citations
2.
Gálvez‐Cancino, Felipe, Ignacio Matos, Danwen Qian, et al.. (2023). Fcγ receptors and immunomodulatory antibodies in cancer. Nature reviews. Cancer. 24(1). 51–71. 40 indexed citations
3.
Cappuzzo, Federico, et al.. (2023). Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. The Oncologist. 28(4). e205–e211. 7 indexed citations
4.
Yofe, Ido, Tomer Landsberger, Adam Yalin, et al.. (2022). Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling. Nature Cancer. 3(11). 1336–1350. 41 indexed citations
5.
Wainberg, Zev A., Ignacio Matos, Jean‐Pierre Delord, et al.. (2021). LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer. Annals of Oncology. 32. S227–S228. 15 indexed citations
6.
Yap, Timothy A., Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.. (2021). Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. The Lancet Respiratory Medicine. 9(6). 613–621. 55 indexed citations
7.
Grande, Enrique, Àlex Teulé, Teresa Alonso‐Gordoa, et al.. (2020). The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). The Oncologist. 25(9). 745–e1265. 24 indexed citations
8.
Braña, Irene, Ignacio Matos, María Vieito, et al.. (2020). 573P Efficacy of immunotherapy (IT) after prior immune checkpoint inhibitors (ICIs) exposure. Annals of Oncology. 31. S489–S490. 1 indexed citations
9.
Hu, Mimi I., Vivek Subbiah, Lori J. Wirth, et al.. (2020). 1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Annals of Oncology. 31. S1084–S1084. 25 indexed citations
10.
Keam, Bhumsuk, Lori J. Wirth, Aaron S. Mansfield, et al.. (2020). 442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Annals of Oncology. 31. S1413–S1414. 1 indexed citations
11.
Matos, Ignacio, María Vieito, Irene Braña, et al.. (2020). 572P Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials. Annals of Oncology. 31. S489–S489. 1 indexed citations
12.
Adashek, Jacob J., Ishwaria M. Subbiah, Ignacio Matos, et al.. (2020). Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?. Trends in cancer. 6(3). 181–191. 88 indexed citations
13.
Capdevila, Jaume, Ignacio Matos, Francesco M. Mancuso, et al.. (2019). Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. Molecular Cancer Therapeutics. 19(1). 312–317. 10 indexed citations
14.
Capdevila, Jaume, Oriol Arqués, José Ramón Hernández Mora, et al.. (2019). Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clinical Cancer Research. 26(4). 902–909. 28 indexed citations
15.
Matos, Ignacio, Lipika Goyal, James M. Cleary, et al.. (2019). Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Annals of Oncology. 30. iv122–iv123. 4 indexed citations
16.
Mayor, Regina, Francesco M. Mancuso, Carmela Iglesias, et al.. (2018). Early evolutionary divergence between papillary and anaplastic thyroid cancers. Annals of Oncology. 29(6). 1454–1460. 48 indexed citations
17.
Matos, Ignacio, Francesco M. Mancuso, Carmela Iglesias, et al.. (2017). Prognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC). Annals of Oncology. 28. v143–v144. 1 indexed citations
18.
Matos, Ignacio, et al.. (2017). The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Targeted Oncology. 12(6). 757–774. 1 indexed citations
19.
Grasselli, Julieta, Élena Elez, Enrique Sanz‐García, et al.. (2016). Molecular, clinical and prognostic characterization of double KRAS/PIK3CA (dKP) mutated metastatic colorectal cancer (mCRC). Annals of Oncology. 27. vi185–vi185. 1 indexed citations
20.
Matos, Ignacio, Élena Elez, Jaume Capdevila, & Josep Tabernero. (2016). Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opinion on Emerging Drugs. 21(3). 267–282. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bin Meng Breakdown of academic impact, for papers by Stefano Sioletic Breakdown of academic impact, for papers by Alessandra Bisagni Breakdown of academic impact, for papers by Heather M. Shaw Breakdown of academic impact, for papers by Hidenori Mizugaki Breakdown of academic impact, for papers by Shafei Wu Breakdown of academic impact, for papers by Ashraf S. Mahmoud-Ahmed Breakdown of academic impact, for papers by Alessia Caleo Breakdown of academic impact, for papers by Pierre Bohanes Breakdown of academic impact, for papers by Zishuo I. Hu
Rankless by CCL
2026